Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum by Lek-Uthai, U. et al.
  Published Ahead of Print 28 April 2008. 
10.1128/AAC.00169-08. 
2008, 52(7):2435. DOI:Antimicrob. Agents Chemother. 
Anstey, R. N. Price and B. Russell
Piera, K. T. Andrews, B. MacHunter, J. S. McCarthy, N. M.
Skinner-Adams, F. Nosten, D. L. Gardiner, P. Boonma, K. A. 
U. Lek-Uthai, R. Suwanarusk, R. Ruengweerayut, T. S.
 
 falciparum
P. than against Those of Plasmodium vivax
Inhibitors against Clinical Isolates of 
Immunodeficiency Virus Type 1 Protease 
Stronger Activity of Human
http://aac.asm.org/content/52/7/2435
Updated information and services can be found at: 
These include:
REFERENCES
http://aac.asm.org/content/52/7/2435#ref-list-1at: 
This article cites 37 articles, 21 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 Septem
ber 4, 2013 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2008, p. 2435–2441 Vol. 52, No. 7
0066-4804/08/$08.000 doi:10.1128/AAC.00169-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Stronger Activity of Human Immunodeficiency Virus Type 1 Protease
Inhibitors against Clinical Isolates of Plasmodium vivax than
against Those of P. falciparum
U. Lek-Uthai,1§ R. Suwanarusk,2,3§ R. Ruengweerayut,4 T. S. Skinner-Adams,5 F. Nosten,6,7,8
D. L. Gardiner,5 P. Boonma,1 K. A. Piera,2 K. T. Andrews,5 B. MacHunter,2
J. S. McCarthy,5 N. M. Anstey,2 R. N. Price,2,7 and B. Russell2,3*
Department of Parasitology, Faculty of Public Health, Mahidol University, Bangkok, Thailand1; International Health Program,
Infectious Diseases Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia2;
Laboratory for Malaria Immunobiology, Singapore Immunology Network, Biopolis, Agency for
Science Technology and Research (A*STAR), Singapore, Singapore3; Mae Sod Hospital, Tak,
Thailand4; Queensland Institute of Medical Research and Australian Centre for International and
Tropical Health and Nutrition, Brisbane, Australia5; Shoklo Malaria Research Unit, Mae Sod,
Thailand6; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital,
Oxford OX3 7LJ, United Kingdom7; and Faculty of Tropical Medicine,
Mahidol University, Rajvithi Road, Bangkok, Thailand8
Received 6 February 2008/Returned for modification 26 March 2008/Accepted 22 April 2008
Recent studies using laboratory clones have demonstrated that several antiretroviral protease inhibitors
(PIs) inhibit the growth of Plasmodium falciparum at concentrations that may be of clinical significance,
especially during human immunodeficiency virus type 1 (HIV-1) and malaria coinfection. Using clinical
isolates, we now demonstrate the in vitro effectiveness of two HIV-1 aspartic PIs, saquinavir (SQV) and
ritonavir (RTV), against P. vivax (n  30) and P. falciparum (n  20) from populations subjected to high levels
of mefloquine and artesunate pressure on the Thailand-Myanmar border. The median 50% inhibitory con-
centration values of P. vivax to RTV and SQV were 2,233 nM (range, 732 to 7,738 nM) and 4,230 nM (range,
1,326 to 8,452 nM), respectively, both within the therapeutic concentration range commonly found for patients
treated with these PIs. RTV was fourfold more effective at inhibiting P. vivax than it was at inhibiting P.
falciparum, compared to a twofold difference in SQV sensitivity. An increased P. falciparum mdr1 copy number
was present in 33% (3/9) of isolates and that of P. vivax mdr1 was present in 9% of isolates (2/22), but neither
was associated with PI sensitivity. The inter-Plasmodium sp. variations in PI sensitivity indicate key differences
between P. vivax and P. falciparum. PI-containing antiretroviral regimens may demonstrate prophylactic
activity against both vivax and falciparum malaria in HIV-infected patients who reside in areas where
multidrug-resistant P. vivax or P. falciparum is found.
Malaria and human immunodeficiency virus type 1 (HIV-1)/
AIDS are two important challenges for public health in South-
east Asia. Both diseases are of particular concern in the west-
ern border provinces of Thailand, where thousands of
displaced people from Myanmar reside. The Thai province of
Tak shares a 570-km border with Myanmar, with approxi-
mately 40% of the total population lacking formal Thai resi-
dent status. As malaria and HIV-1/AIDS are associated with
displaced populations, it is not surprising that Tak is the most
malarious province in Thailand, accounting for almost a third
of malaria cases in 2006 (Communicable Disease Survey, in-
ternal report, Department of Disease Control, Royal Thai
Ministry of Public Health, Bangkok, Thailand, 2006). The
prevalence of HIV-1 infection in pregnant women reporting to
one migrant clinic in Tak Province was 2.34% (43/1,838) in
2006 (HIV Prevalence in the Mae Tao Health Clinic, unpub-
lished internal report, Mae Tao Health Clinic, Mae Sod, Thai-
land, 2006).
The adverse effects of malaria and HIV infection are syner-
gistic and bidirectional (32). Malaria-infected people have a
higher viral load, an important cofactor in the pathogenesis
and transmission of HIV-1, particularly in pregnant women (7,
17, 37). Although no published data exist on malarial parasite–
HIV-1 coinfections in Thailand, data from sub-Saharan Africa
suggest that HIV-infected individuals are at higher risk of
clinical malaria (34). There are two important differences be-
tween the malaria situation in sub-Saharan Africa and the
Thailand-Myanmar border; first, 50% of malaria cases in Tak
Province are due to Plasmodium vivax, and second, there is a
high prevalence of P. falciparum resistance to chloroquine
(CQ), antifolates, mefloquine, and amodiaquine (6, 22, 28).
The emergence of multidrug-resistant P. falciparum para-
sites and the importance of understanding the consequences
and interactions of malaria-HIV coinfection and treatment
have recently provided an impetus for investigations of the
antimalarial activity of antiretroviral agents (2, 8, 20, 21).
These studies have shown that aspartic protease inhibitors
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(PIs) such as saquinavir (SQV) and ritonavir (RTV) can inhibit
the in vitro development of P. falciparum at clinically relevant
concentrations (20, 27, 33). It has also been demonstrated that
these compounds act synergistically in combination with the
well-known antimalarials mefloquine and CQ (31). To date, in
vitro PI antimalarial studies have used laboratory clones of P.
falciparum. The effectiveness of PIs against clinical isolates and
against the other major Plasmodium species of human impor-
tance, P. vivax, has not been assessed (16, 24).
HIV PIs and antimalarials, such as mefloquine, are sub-
strates for P glycoprotein (Pgp) efflux pumps; consequently,
their pharmacodynamics and pharmacokinetics are modulated
by Pgp cellular transport (19, 38). Preliminary work on a Pgp in
P. falciparum (Pfmdr1) suggests that its amplification is not
associated with the synergistic action of PIs with mefloquine
(31). As populations of P. falciparum and P. vivax on the
Thailand-Myanmar border have an increased mdr1 copy num-
ber relative to that of other regions not subjected to meflo-
quine pressure (25, 35), it is important to better understand the
PI sensitivity phenotype in relation to this Pgp polymorphism.
As both RTV and SQV demonstrate effective Pgp efflux inhi-
bition (10, 11), we would expect that any association with mdr1
copy number and Plasmodium sp. sensitivity to PIs would be
detected by assessing the antimalarial activity of these drugs
against field isolates.
The aim of the present study was to investigate the in vitro
effectiveness of two antiretroviral PIs, RTV and SQV, against
clinical isolates of P. vivax and P. falciparum in an area sub-
jected to high levels of mefloquine and artesunate pressure and
to determine if the RTV and SQV sensitivities of P. falciparum
and P. vivax are associated with mdr1 copy number.
MATERIALS AND METHODS
Field location and sample collection. In December 2006, 30 P. vivax and 20 P.
falciparum isolates were collected from malaria outpatients attending the Mae
Sod Hospital located in the Thai province of Tak on the northwestern Thailand-
Myanmar border. Patients with symptomatic malaria presenting to an outpatient
facility were recruited into the study if they were singly infected with P. falcipa-
rum or P. vivax and had a parasitemia of between 2,000 and 20,000 parasites per
microliter. Five milliliters of infected blood was collected by venipuncture into
lithium-heparin Vacutainers (Becton Dickinson). After the removal of host
white blood cells using a CF-11 column, 2 ml of packed infected red blood cells
was divided as follows: 1 ml was cryopreserved in Glycerolyte, 200 l was spotted
onto filter paper, and 800 l was used for the in vitro drug susceptibility assay.
In vitro drug susceptibility assay. A modified WHO schizont maturation assay
was used to test the antimalarial susceptibility of P. vivax and P. falciparum
isolates as described previously (29, 30). A 2% hematocrit blood-medium mix-
ture (BMM) consisting of McCoy’s 5A medium and 20% AB-positive human
serum was made for P. vivax and P. falciparum isolates. A total of 200 l of BMM
was added to each well of predosed drug plates containing serial dilutions of
RTV (34,676 nM), SQV (37,265 nM), CQ (2,992 nM), artesunate (67 nM), and
mefloquine (338 nM) (maximum concentrations are shown in parentheses).
Predosed drug plates containing the BMM were placed in a gas chamber con-
taining 5% CO2, 5% O2, and 90% N2 at 37.5°C until 50% of parasites in the
drug-free control had matured to schizonts (24 to 42 h). To minimize the loss of
antimalarial action, the predosed plates were stored at 4°C and used within a
month of their manufacture. Predosed plates were quality assured by using the
K1 clone of P. falciparum before and after field trials.
Thick blood films made from each well were stained with 5% Giemsa stain for
30 min and examined microscopically. Differential counts of 200 asexual para-
sites in the preincubation and test slides were classified into ring stage (ring-
shaped trophozoites), mature trophozoites (one or two chromatin dots and
hemazoin pigment visible), and schizonts (three or more chromatin dots visible).
Free merozoites and gametocytes were not included in the count. To ensure
optimal maturity and ease of parasite identification and to reduce parasite
classification error, only schizonts with at least five well-defined chromatin dots
were classified as schizonts at the time of harvest. The number of schizonts (five
or more chromatin dots visible) per 200 asexual-stage parasites was determined
for each drug concentration and normalized to the number in the control well.
The dose-response data were analyzed by using nonlinear regression analysis
(WinNonlin 4.1; Pharsight), and 50% inhibitory concentration (IC50) values were
derived by using an inhibitory sigmoid Emax model.
Determining the mdr1 copy number. P. vivax mdr1 (Pvmdr1; GenBank acces-
sion no. AY618622) and Pfmdr1 (GenBank accession no. M29154) gene copy
numbers were determined by quantitative real-time PCR using a Rotor-Gene
6000 (Corbett) as previously described (25, 35). The assessment of the copy
number was repeated at least twice for all isolates. The repeatability coefficient
was determined to be 0.30 (viz. 95% of repeated estimates of the mdr1 copy
number were within 0.15 of the first estimate).
Data analysis. Plasmodium vivax results were stratified into two groups ac-
cording to whether parasites were set up in culture with a predominance of rings
(a ring-to-trophozoite stage ratio [RT] of 1) or trophozoites (RT  1). Except
for antimalarial stage specificity analysis, only P. vivax isolates with an RT of 1
were prospectively used for analysis, so that all erythrocytic stages of P. vivax
were exposed to the therapeutic of interest. Analysis was performed using SPSS
for Windows (version 14; SPSS Inc., Chicago, IL). The Mann-Whitney U test or
Kruskal-Wallis method was used for nonparametric comparisons. The signifi-
cance of nonparametric correlation coefficients was examined using a Spear-
man’s rho. The statistical significance level of 0.05 was set prior to analysis.
Scatter plots were constructed using GraphPad Prism (version 5; GraphPad
Software Inc., San Diego, CA).
Ethical approval. All research was conducted in accordance with the national
and institutional guidelines for human experimentation. Samples were taken only
upon written consent after the study was explained in Karen, Burmese, or Thai.
Consent and information forms were translated into Karen, Burmese, and Thai.
Ethical approval for this study was obtained from the Ethical Review Committee
for Research in Human Subjects, Ministry of Public Health, Thailand (reference
no. 4/2549, 6 February 2006).
RESULTS
Of the 30 P. vivax and 20 P. falciparum clinical isolates
collected, 80% (24/30) and 95% (19/20), respectively, were
successfully cultured in the in vitro assay. Whereas all isolates
of P. falciparum were synchronous, with all parasites at the ring
stage prior to culture, the P. vivax isolates were mostly asyn-
chronous, with a median percentage of rings of 60% (inter-
quartile range [IQR], 28 to 85%). The median duration of the
assay was 36 h (IQR, 24 to 43 h), with no difference between
species. Sixty-seven percent of P. vivax isolates (16/24) had an
RT of 1 prior to culture. The median percentage of rings in
P. vivax isolates with an RT of 1 was 75% (IQR, 60 to 91%),
significantly higher than in isolates with an RT of 1 (26%)
(IQR, 10 to 29%; P, 0.001). Plasmodium vivax isolates with
an RT of 1 had a significantly higher median CQ IC50 of 442
nM (IQR, 157 to 2,034 nM) versus 38 nM (IQR, 19 to 51 nM)
in isolates with an RT of 1 (Fig. 1). In view of the significant
stage specificity of CQ and a similar trend with the other
antimalarials, further analysis of P. vivax was restricted to iso-
lates with an RT of1 (29). The median IC50s of P. falciparum
and P. vivax (RT  1) for each of the PIs and control antima-
larial agents are presented in Table 1. Plasmodium vivax was
significantly more sensitive to RTV, SQV, CQ, and mefloquine
(Table 1). The in vitro sensitivities of both species to RTV,
SQV, and artesunate were significantly correlated; i.e., para-
sites with increased sensitivity to other PIs also had increased
sensitivity to these PIs (Table 2).
The Pvmdr1 copy number could be reliably determined in
92% (22/24) of the P. vivax isolates tested, with amplification
present in two (9%) isolates, one containing a double ampli-
fication and the other containing a triple amplification. Neither
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of these isolates demonstrated RTV or SQV IC50 values out-
side of the range determined for the remainder of the isolates
(Fig. 2A). The median IC50 to mefloquine in the 13 isolates
with a single Pvmdr1 copy number was 43 nM (range, 7.0 to 112
nM), compared to IC50s in the two isolates with Pvmdr1 am-
plification levels of 137 nM and 176 nM (Fig. 2A).
The Pfmdr1 copy number was successfully assayed in 77%
(10/13) of the P. falciparum isolates in which DNA samples
were available. Forty percent (3/9) of the P. falciparum isolates
had Pfmdr1 amplification (two double mutants and one qua-
druple mutant). Isolates with an increased Pfmdr1 copy num-
ber had significantly higher IC50s to mefloquine (median, 182
nM; range, 137 to 335 nM) compared to those with a single
copy number (median, 77 nM; range, 60 to 136 nM; P, 0.036).
Although there were only three P. falciparum isolates with
increased copy numbers, there was no significant difference or
FIG. 1. Effect of the initial development stage of the P. vivax isolate, either predominantly ring stage (RT  1) (filled circles) or predominantly
trophozoite stage (RT 1) (open circles) on RTV, SQV, CQ, artesunate (AS), and mefloquine (MQ) sensitivity. Lines indicate median IC50s (nM)
for an RT of 1 (solid) or an RT of 1 (dashed). NS, no significant difference. Subsequent analysis of P. vivax was restricted to isolates with an
RT of 1.
TABLE 1. Comparison of the in vitro antimalarial susceptibilities of P. vivax and P. falciparum isolates from Mae Sod, Thailand
Therapeutic
P. vivaxa P. falciparum
PbNo. of
isolates Median IC50 (range) (nM)
No. of
isolates Median IC50 (range) (nM)
Ritonavir 14 2,233 (732–7,738) 19 9,664 (909–21,103) 0.001
Saquinavir 15 4,230 (1,326–8,452) 19 8,305 (1,105–26,269) 0.018
Chloroquine 14 38 (7–1,264) 18 152 (32–380) 0.001
Artesunate 15 8 (1–23) 19 8 (1–27) 0.682
Mefloquine 16 69 (30–177) 17 137 (42–341) 0.028
a Analysis of Plasmodium vivax was restricted to isolates with an RT of 1.
b Underlined values indicate that the correlation is significant at least at the 0.05 level.
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trend for reduced sensitivity in these isolates in comparison to
the sensitivity of the isolates with a single copy number for
either RTV or SQV (Fig. 2B).
DISCUSSION
The spread of drug-resistant P. vivax isolates throughout
areas of Asia already affected by a high prevalence of HIV-1
infection is a cause for great concern. Little is known about the
clinical or public health implications of HIV-1 and P. vivax
coinfections. Compared to those in Indonesia, P. vivax popu-
lations in Thailand are generally considered to be more sensi-
tive to antimalarials (3, 26, 35). Indeed, our data show that
Thai P. vivax isolates are generally more sensitive to CQ than
Indonesian isolates (except for 14% [2/14] of isolates with an
RT of 1 and with a CQ IC50 greater than 100 nM) (35) (Fig.
1). However, our data also indicate that Thai P. vivax isolates
have a significantly lower sensitivity to mefloquine and artesu-
nate (Table 1) (29). These findings highlight the emergence of
multidrug-resistant strains of Plasmodium spp., a likely reflec-
tion of local drug pressure.
The rise in the prevalence of HIV infection in many areas
where malaria is endemic also increases the need for novel
ways to effectively treat HIV-malaria parasite coinfections. For
example, the recent adverse events observed in HIV-infected
children following treatment with artesunate-amodiaquine for
uncomplicated malaria demonstrate that more attention to this
issue is required (13). In this study, we demonstrate the anti-
malarial activity of an important class of antiretroviral drugs,
the PIs, at concentrations likely to be clinically relevant. The
median IC50s for RTV and SQV in Thai P. falciparum isolates
were higher than for the three standard antimalarials tested
(Table 1) and higher than those previously reported for lab
strains of P. falciparum (20, 31, 33). In contrast, the median
IC50s for RTV and SQV against P. vivax (Table 1) were within
the in vivo therapeutic range commonly seen in patients
treated with these PIs (maximum concentration of RTV and
SQV in serum, 15,500 nM and 3,700 to 5,500 nM, respectively)
(20). Interestingly, P. vivax isolates were almost twice as sen-
sitive to RTV as to SQV. RTV was also fourfold more effective
at inhibiting P. vivax than P. falciparum, compared to an only
twofold difference in effectiveness for SQV (Table 1).
Although the antimalarial actions of PIs are still not fully
understood, it was initially thought that PIs inhibited the as-
partic proteases associated with the food vacuole (12). The P.
falciparum food vacuole-associated plasmepsins (PMs) I, II,
and IV and histoaspartic protease are thought to be involved in
the initial steps of hemoglobin degradation (4). However,
more-recent data from isobologram and transgenic-parasite
studies suggest that these food vacuole PMs are unlikely to be
the primary targets of these drugs (5, 15, 18, 21, 31). Interest-
ingly, PMIV (GenBank accession no. AAC15792) is the only
digestive vacuole PM ortholog found in P. vivax (9, 14). How-
ever, it is unlikely that PMIV in P. vivax is associated with the
vacuole, as it is transcribed only in the early schizont stage (Z.
Bozdech and P. R. Preiser, personal communications). The
effective absence of vacuolar PMs in P. vivax and the significant
antimalarial efficacy of RTV and SQV against all stages of P.
vivax erythrocytic development (including the early ring stage
where PMIV is not yet present) (Fig. 1) support the current
view that Plasmodium sp. vacuolar PMs are not the targets of
PIs. Nonvacuolar aspartic proteases also exist in malaria par-
asites, and it may be that one or more of these enzymes are the
targets for PIs.
An important molecular marker associated with drug resis-
tance in P. falciparum is Pfmdr1. Multiple copy numbers of
Pfmdr1 are associated with reduced sensitivity to mefloquine,
lumefantrine, and artesunate in P. falciparum (1, 23, 36). An
earlier study using laboratory clones with a known mdr1 am-
plification genotype suggested that mdr1 amplification does
not affect PI sensitivity. In this study of clinical isolates, we
provide additional evidence to support this assertion, demon-
strating that an increase in the Pfmdr1 or Pvmdr1 copy number
is not associated with changes in the in vitro sensitivity of P.
vivax or P. falciparum to RTV or SQV. In keeping with previ-
ous observations, P. falciparum isolates with Pfmdr1 amplifica-
tion were less sensitive to mefloquine. Although a similar trend
appeared to be present for P. vivax, only two isolates with an
increased Pvmdr1 copy number could be tested; hence, further
studies will be required to confirm these findings. The absence
of any cross-resistance between mefloquine and PIs suggests
that PIs may be beneficial for patients coinfected with malaria
and HIV in areas of mefloquine resistance, particularly given
TABLE 2. In vitro susceptibility correlation coefficients (Spearman’s rho) of P. vivax and P. falciparum to RTV, SQV, and three commonly
used antimalarial therapeuticsb
Therapeutic combinations
P. vivaxa P. falciparum
Correlation P No. ofisolates Correlation P
No. of
isolates
Ritonavir plus:
Chloroquine 0.294 0.354 12 0.304 0.219 18
Artesunate 0.533 0.061 13 0.489 0.033 19
Mefloquine 0.349 0.221 14 0.282 0.257 18
Saquinavir 0.753 0.003 13 0.772 0.001 19
Saquinavir plus:
Chloroquine 0.291 0.334 13 0.353 0.151 18
Artesunate 0.697 0.006 14 0.626 0.004 19
Mefloquine 0.346 0.206 15 0.396 0.103 18
a Analysis of Plasmodium vivax was restricted to isolates with an RT of 1.
b Underlined P values indicate that the correlation is significant at least at the 0.05 level.
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FIG. 2. Effect of Pvmdr1 (A) and Pfmdr1 (B) copy amplification on the sensitivity of P. vivax and P. falciparum to RTV, SQV, CQ, artesunate
(AS), and mefloquine (MQ). Filled triangles represent isolates with mdr1 amplification (solid lines represent median IC50s [nM]). Open triangles
represent isolates with a single copy of mdr1 (dashed lines represent median IC50s [nM]).
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the possible synergistic interactions which may occur as a result
of PI and mefloquine coadministration (31). PIs are not used
as single-agent therapy for HIV but rather as components of
highly active antiretroviral therapy (HAART). While PI-based
HAART is not generally considered frontline therapy in the
developing world, the enhanced potency of some PI-based
HAART regimens, such as RTV-boosted lopinavir, now avail-
able in a lower-cost thermostable formulation for marketing in
developing countries (Aluvia; Abbott), indicates that usage will
expand. RTV, which is generally used as a “low-dose” compo-
nent of PI-based HAART, is used to boost the pharmacoki-
netic profile of its partner PI through its potent inhibition of
cytochrome P450 enzymes. Our data showing the cross-Plas-
modium sp. effectiveness of PIs suggest that the treatment of
HIV-infected patients with PI-containing antiretroviral regi-
mens might help prevent malarial parasite coinfection in re-
gions where both P. falciparum and P. vivax are endemic. Fur-
thermore, the differential sensitivities of P. vivax and P.
falciparum isolates and the modulatory effect of RTV on an-
timalarial activity provide some further information on the
likely mechanism of the antimalarial action of this class of
drugs.
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